ImageneBio Q3 2026 earnings

IMA · 2026-11-09 16:17 AMC ET · 8-K on SEC

Net loss widened to $15.6 million as R&D expenses surged to $11.3 million, partially offset by a $10.2 million reduction in G&A costs.

Headline numbers

not stated in the 8-K

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $17.3 million (+66% YoY)
  • One-offs in the quarter not stated in the 8-K
  • Effective tax rate 0.1% (prior-year -0.3%, year-to-date 0.1%)
  • Non-GAAP bridge No reconciliation provided; GAAP net loss used.

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents and marketable securities$126.6 million$136.2 million$-9.6%
Weighted-average common shares outstanding17.1 million16.2 million8.8 million+5.5%

Guidance

not stated in the 8-K

What drove it

  • Revenue story No revenue reported; license revenue was $0 for the quarter.
  • EPS story Net loss widened primarily due to a $4.0 million increase in R&D expenses and a $3.9 million increase in total operating expenses, partially offset by a $5.0 million reduction in G&A expenses.
  • One-off check No one-off items identified in the release.

The good

  • G&A expenses reduced by $5.0 million YoY to $6.0 million.
  • Cash position sufficient to fund operations into Q1 2028.

The bad

  • Net loss widened to $15.6 million from $10.2 million in Q2.
  • R&D expenses surged 69% QoQ to $11.3 million.

The ugly

  • none

Open questions

  • What specific drivers caused the 69% QoQ increase in R&D expenses?
  • Why did the weighted-average common shares outstanding increase 5.5% QoQ?
Full release

ImageneBio (IMA) earnings release, November 9, 2026

ImageneBio, Inc. (IMA) · Form 8-K, Item 2.02 · Filed · SEC filing

ImageneBio Reports Third Quarter 2026 Financial Results

SAN DIEGO, November 9, 2026 — ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended September 30, 2026, and provided a company update.

Company Highlights

“We are advancing our trials, developing a robust data set that we believe could demonstrate olevaprubart’s disease-modifying potential and tolerability profile across inflammatory indications. Our safety database continues to grow as we progress, and we are gaining experience across biologic- and

JAK-experienced patients as well as those that are naïve to advanced therapies,” Kristin Yarema, Ph.D., chief executive officer of Imagene, commented. “With

ADAPTIVE on course for topline data in the fourth quarter of 2027 and our alopecia areata trial on track to begin by year end, we are executing with capital discipline, and we are poised to deliver data that could demonstrate the true value potential of oleva.”

Olevaprubart Program Updates

Third Quarter 2026 Financial Highlights

Cash Position:

The Company ended September 30, 2026, with $126.6 million in cash, cash equivalents and marketable securities. The Company expects that such resources will be sufficient to fund planned operations into the first quarter of 2028.

Research and Development (R&D)

Expenses:

R&D expenses were $11.3 million for the three months ended September 30, 2026, compared to $15.2 million for the same period in 2025.

General and Administrative (G&A) Expenses:

G&A expenses were $6.0 million for the three months ended September 30, 2026, compared to

$11.0 million for the same period in 2025.

Net Loss:

Net loss was $15.6 million for the three months ended September 30, 2026, compared to a net loss of $24.8 million for the same period in 2025. Net loss per share attributable to common stockholders, basic and diluted, was $0.91 for the three months ended September 30, 2026, compared to $2.91 for the same period in 2025.

About Olevaprubart

Olevaprubart is an investigational, non-T cell-depleting monoclonal antibody targeting OX40, a receptor protein primarily found on activated human T cells. When OX40 binds its ligand OX40L in human tissue, the signal generated plays a key role in the activation, expansion, and survival of many subtypes of T cells. Targeted inhibition of OX40 is being studied in the clinic across a range of autoimmune, inflammatory, and immunological conditions where aberrant signaling of one or more T cell subtypes is believed to drive disease. Olevaprubart has been engineered to include a silenced antibody-dependent cell-mediated cytotoxicity function demonstrated to avoid T cell depletion or killing and intended to minimize safety risk. This technology also resulted in an approximately

5-week half-life, prolonging therapeutic activity with the aim of maximizing time between doses for a patient.

About ImageneBio, Inc.

Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company’s program, olevaprubart, is a receptor-targeting, non-depleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended September 30, — (In thousands, except share and per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
License revenue$—$—$—800
Operating expenses:
Research and development11,27015,15623,90024,849
General and administrative6,03911,03617,27215,496
Total operating expenses17,30926,19241,17240,345
Loss from operations-17,309-26,192-41,172-39,545
Other income (expense):
Interest income, net1,1891,0553,566742
Other income, net5202841,235288
Total other income, net1,7091,3394,8011,030
Loss before income taxes-15,600-24,853-36,371-38,515
Income tax expense (benefit)20-7446-74
Net loss-15,620-24,779-36,417-38,441
Accretion of redeemable convertible preferred shares-846-7,046
Net loss attributable to common stockholders-15,620-25,625-36,417-45,487
Net loss per common share, basic and diluted-0.91-2.91-2.45-9.98
Weighted-average common shares outstanding, basic and diluted17,122,6918,797,12614,853,5524,559,574
Comprehensive loss:
Net loss-15,620-24,779-36,417-38,441
Other comprehensive loss:
Unrealized gain (loss) on marketable securities-11994-25794
Foreign currency translation adjustment-3-29
Total comprehensive loss-15,739-24,688-36,674-38,376

Balance Sheet

September 30, 2026 — (In thousands, except share and per share amounts)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents84,85394,532
Marketable securities41,74440,817
Prepaid expenses and other current assets4,0004,939
Total current assets130,597140,288
Operating lease right-of-use assets, net345790
Deposits and other non-current assets6,1194,878
Promissory note receivable from related party5,4807,020
Total assets142,541152,976
Current liabilities:
Accounts payable9311,439
Accrued expenses and other current liabilities5,8327,533
Operating lease liabilities, current1,3122,262
Total current liabilities8,07511,234
Operating lease liabilities, non-current713
Other non-current liabilities848870
CVR liability due to related party5,4807,020
Total liabilities14,40319,837
Stockholders’ equity:
Voting Common Stock, $0.001 par value, 142,000,000 shares authorized; 12,456,281 and 10,650,925 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively1211
Additional paid-in capital394,766363,094
Accumulated other comprehensive income (loss)-17087
Accumulated deficit-266,470-230,053
Total stockholders’ equity128,138133,139
Total liabilities and stockholders’ equity142,541152,976

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the

Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the expected timing, progress and results of the Company’s ongoing Phase 2b ADAPTIVE trial and long-term extension study; the anticipated benefits and potential impact of the amended ADAPTIVE trial protocol; the expected timing of initiation of the Company’s Phase 2 alopecia areata trial and the timing of initial clinical data; the therapeutic potential, safety profile and clinical differentiation of olevaprubart; the Company’s plans to advance the development of olevaprubart across multiple inflammatory and autoimmune indications; the Company’s expected cash resources, capital requirements and financing plans; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. Words such as “will,” “can,” “expect,” “may,” “plan,”

“potential,” “goal,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: risks associated with the nonclinical and clinical development and regulatory approval of olevaprubart, including potential delays in the completion of clinical trials and potential safety and other complications thereof; the timing of the availability of data from the Company’s clinical trials; the risk that interim, topline and preliminary data from the Company’s preclinical studies or clinical trials that are announced or published from time to time may not be predictive of future results and may change as more patient data become available and are subject to audit and verification procedures, which could result in material changes to the final data; the risk that competitor data may materially and adversely impact the Company, its business, and its future prospects; the clinical utility, potential differentiation and/or benefits and market acceptance of olevaprubart; the requirement for additional capital to continue to advance... (truncated)available on favorable terms or at all; the Company’s ability to attract, hire, and retain skilled executive officers and employees; the Company’s ability to protect its intellectual property and proprietary technologies; the Company’s reliance on third parties, contract manufacturers, and contract research organizations; the possibility that the Company may be adversely affected by other economic, political, business, or competitive factors; and risks associated with changes in applicable laws or regulations or government resources and policies. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in the Company’s filings with the Securities and

Exchange Commission (the “SEC”), including the risks set forth under the heading “Risk Factors” in the Company’s Annual Report on Form

10-K for the year ended December 31,

2025, and the Company’s subsequent Quarterly Reports on Form

10-Q, filed with the SEC, and in the Company’s other filings with the SEC. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

IMAGENEBIO, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share and per share amounts)

IMAGENEBIO, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share amounts)

Contacts

Investor

Contact:

Rebecca Cohen rcohen@imagenebio.com

Media Contact:

Jason Braco, PhD

Valence Communications jason@valencecomms.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.